Incyte (INCY) Competitors $75.59 +0.70 (+0.93%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$77.06 +1.47 (+1.95%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ABBV, ALNY, BIIB, UTHR, NBIX, EXEL, BMRN, EXAS, HALO, and RGENShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "medical" sector. Incyte vs. Its Competitors AbbVie Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Repligen AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends. Does the media refer more to ABBV or INCY? In the previous week, AbbVie had 79 more articles in the media than Incyte. MarketBeat recorded 131 mentions for AbbVie and 52 mentions for Incyte. AbbVie's average media sentiment score of 1.02 beat Incyte's score of 0.81 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 85 Very Positive mention(s) 7 Positive mention(s) 30 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive Incyte 22 Very Positive mention(s) 8 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive Is ABBV or INCY more profitable? Incyte has a net margin of 18.99% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 518.10% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets AbbVie6.45% 518.10% 13.61% Incyte 18.99%21.99%14.43% Which has more risk & volatility, ABBV or INCY? AbbVie has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Do analysts rate ABBV or INCY? AbbVie presently has a consensus target price of $212.81, indicating a potential upside of 9.04%. Incyte has a consensus target price of $79.73, indicating a potential upside of 5.48%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 8 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.81Incyte 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.28 Do institutionals & insiders believe in ABBV or INCY? 70.2% of AbbVie shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.3% of AbbVie shares are owned by insiders. Comparatively, 17.8% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation and earnings, ABBV or INCY? AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B6.12$4.28B$2.3583.05Incyte$4.24B3.48$32.62M$4.4017.18 SummaryAbbVie beats Incyte on 11 of the 17 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.62B$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio17.1817.6228.7523.81Price / Sales3.48179.21372.2066.02Price / Cash135.2841.9535.4557.96Price / Book3.548.508.275.55Net Income$32.62M-$55.06M$3.25B$259.20M7 Day Performance7.68%-3.99%-3.72%-4.64%1 Month Performance10.88%9.58%4.30%4.41%1 Year Performance17.25%6.70%25.87%17.95% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7558 of 5 stars$75.59+0.9%$79.73+5.5%+17.3%$14.62B$4.24B17.182,617Trending NewsAnalyst ForecastABBVAbbVie4.5744 of 5 stars$188.47-1.0%$211.29+12.1%+2.9%$336.11B$56.33B18.5355,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionALNYAlnylam Pharmaceuticals3.8731 of 5 stars$324.79-1.2%$347.75+7.1%+49.6%$42.87B$2.25B0.002,230Trending NewsAnalyst ForecastBIIBBiogen4.8472 of 5 stars$129.28-1.7%$186.37+44.2%-37.4%$19.27B$9.68B8.317,605Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.9631 of 5 stars$298.14-2.1%$383.08+28.5%-10.2%$13.73B$2.88B12.151,305Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap UpNBIXNeurocrine Biosciences4.687 of 5 stars$133.71+1.2%$163.87+22.6%-15.8%$13.08B$2.36B44.791,800Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionEXELExelixis4.9365 of 5 stars$44.39-2.7%$45.33+2.1%+53.8%$12.44B$2.17B21.111,147Trending NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9771 of 5 stars$58.14-1.5%$93.74+61.2%-31.3%$11.32B$2.85B18.383,040News CoverageUpcoming EarningsEXASExact Sciences4.4246 of 5 stars$48.04-0.9%$70.50+46.8%-17.5%$9.15B$2.76B0.007,000Positive NewsUpcoming EarningsHALOHalozyme Therapeutics4.775 of 5 stars$57.73-0.9%$62.70+8.6%+7.2%$7.18B$1.02B13.74390News CoveragePositive NewsUpcoming EarningsRGENRepligen4.693 of 5 stars$119.65-1.7%$169.92+42.0%-28.2%$6.84B$634.44M76.561,778Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies AbbVie Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Repligen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
